Breaking News

Signum, GSK in R&D Pact

Companies to screen and identify PP2A targeted compounds

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Signum Biosciences has entered into an agreement with GlaxoSmithKline (China) R&D Co. Ltd. to collaborate on Signum’s phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A). Signum will receive research support and milestone payments. GSK will have exclusive rights to Signum’s phosphatase screening technology for R&D activities in neurosciences. Both companies will screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters